Menu
GWAS Study

Genome-wide association study of conduct disorder symptomatology.

Dick DM, Aliev F, Krueger RF et al.

20585324 PubMed ID
GWAS Study Type
3963 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

DD
Dick DM
AF
Aliev F
KR
Krueger RF
EA
Edwards A
AA
Agrawal A
LM
Lynskey M
LP
Lin P
SM
Schuckit M
HV
Hesselbrock V
NJ
Nurnberger J
AL
Almasy L
PB
Porjesz B
EH
Edenberg HJ
BK
Bucholz K
KJ
Kramer J
KS
Kuperman S
BL
Bierut L
Chapter II

Abstract

Summary of the research findings

Conduct disorder (CD) is one of the most prevalent childhood psychiatric conditions, and is associated with a number of serious concomitant and future problems. CD symptomatology is known to have a considerable genetic component, with heritability estimates in the range of 50%. Despite this, there is a relative paucity of studies aimed at identifying genes involved in the susceptibility to CD. In this study, we report results from a genome-wide association study of CD symptoms. CD symptoms were retrospectively reported by a psychiatric interview among a sample of cases and controls, in which cases met the criteria for alcohol dependence. Our primary phenotype was the natural log transformation of the number of CD symptoms that were endorsed, with data available for 3963 individuals who were genotyped on the Illumina Human 1M beadchip array. Secondary analyses are presented for case versus control status, in which caseness was established as endorsing three or more CD symptoms (N = 872 with CD and N = 3091 without CD). We find four markers that meet the criteria for genome-wide significance (P<5 × 10(-8)) with the CD symptom count, two of which are located in the gene C1QTNF7 (C1q and tumor necrosis factor-related protein 7). There were six additional SNPs in the gene that yielded converging evidence of association. These data provide the first evidence of a specific gene that is associated with CD symptomatology. None of the top signals resided in traditional candidate genes, underscoring the importance of a genome-wide approach for identifying novel variants involved in this serious childhood disorder.

872 European, African American and other ancestry substance dependence cases, 3,091 European, African American and other ancestry controls

Chapter III

Study Statistics

Key metrics and study information

3963
Total Participants
GWAS
Study Type
No
Replicated
African American or Afro-Caribbean, Other, European
Ancestry
U.S.
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.